Brain Metastases, NSCLC Stage IV, Sintilimab, SRS
Conditions
Brief summary
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
Interventions
COMBINATION_PRODUCTSRS sequential sintilimab
The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
Sponsors
Xiaorong Dong
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* non-small cell lung cancer patients with less than brain metastases * Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment * Patients who have not received intracranial local treatment before
Exclusion criteria
* Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds * Patients with hemorrhage in intracranial metastasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| iPFSof NSCLC patients receiving SRS sequential sintilimab | 1 year | From the beginning of treatment to the end of follow-up study, when the longest diameter of brain metastases treated by SRS was more than 30% smaller than the baseline level at any time of efficacy evaluation, the objective remission of the lesions was achieved. The time from the objective remission to the next progress of the intracranial lesions was recorded as the intracranial progression-free survival(iPFS). |
Countries
China
Contacts
Primary Contactxiaorong dong, Dr
Outcome results
None listed